Featured Research

from universities, journals, and other organizations

Reducing Side Effects Of Retinoic Acid Cancer Treatment

Date:
August 15, 2002
Source:
Cornell University
Summary:
For some time doctors have been using a vitamin A derivative, retinoic acid (RA), to treat several cancers, particularly prostate cancer and leukemia, and they are now experimenting with the drug to treat breast cancer. The great drawback to RA, however, is that it requires high levels of the medication in order to turn genes "on" and "off," often triggering devastating and potentially fatal side effects.

ITHACA, N.Y. -- For some time doctors have been using a vitamin A derivative, retinoic acid (RA), to treat several cancers, particularly prostate cancer and leukemia, and they are now experimenting with the drug to treat breast cancer. The great drawback to RA, however, is that it requires high levels of the medication in order to turn genes "on" and "off," often triggering devastating and potentially fatal side effects.

Related Articles


Now, a Cornell University biochemist has learned how to make tumor cells up to 1,000 times more sensitive to RA so that much smaller doses would be required to flick the "on" and "off" switch (a process known as the induction of gene expression).

"This novel strategy for regulating the anticarcinogenic activity of retinoic acid has potential not only for treating tumors but also, perhaps, for protecting high-risk patients preventively," says Noa Noy, a professor of nutritional sciences at Cornell. "We have discovered that a naturally occurring protein in the cell can dramatically enhance the ability of RA to inhibit the proliferation of breast cancer cells, so that much less RA -- perhaps even the amount naturally present in the body -- is required to suppress tumor development."

The new findings are described in two recent articles in Molecular and Cellular Biology (April and July 2002).

RA belongs to a class of compounds known as retinoids that play key roles in regulating gene transcription and, therefore, govern multiple functions in the body, such as cell division and differentiation, immune response and embryonic development. They also control the development and spread of cancer cells, and some, including RA, can inhibit tumor growth by preventing cancer cell proliferation. Retinoids are now in clinical trials for treatment of head, neck and breast cancers, as well as for diabetes, arteriosclerosis and emphysema.

In the body, RA activates a protein in cells known as retinoic acid receptor (RAR) that binds to certain DNA sequences and turns target genes on or off. A typical treatment with RA seeks to activate RAR in order to switch on favorable genes. However, at pharmacological doses, RA and other retinoids are highly toxic. Moreover, cancer patients frequently become resistant to RA therapy over time.

Noy decided to take a different approach by seeking to understand how the gene-transcription activity of RA is regulated by two proteins called cellular retinoic acid-binding proteins (CRABP-I and CRABP-II). These proteins were identified decades ago, but their exact functions remained obscure.

"We have found that as soon as RA binds to CRABP-II, the protein rapidly moves into the cell nucleus, unlike CRABP-I, which keeps RA out of the nucleus. Once in the nucleus, CRABP-II binds to RAR and channels RA to it, thereby activating the transcription factor to turn genes on or off," explains Noy.

Noy has found that CRABP-II greatly enhances the transcriptional activity of retinoic acid receptors by directly targeting RA to them. Therefore, she has been working on introducing CRABP-II to cells to treat cancer. She is looking into patenting her approaches.

Noy also has indications that CRABP-II can slow tumor growth in the presence of very small amounts of RA. In new, as yet unpublished, research, Noy -- in collaboration with nutritional sciences colleague Danny Manor, and Rodney Page and Alexander Nikitin of Cornell's College of Veterinary Medicine -- studied the effectiveness of CRABP-II in mice with cancer. When tumors in the mice reached half a centimeter, one group received injections of a virus that expressed CRABP-II in the tumors.

"The rate of growth of tumors in the mice that received CRABP-II was dramatically slower," says Noy. "The implication here is that we may not even need to administer RA to treat tumors, but can make use of the RA already present in the body and use CRABP-II to sensitize the tumor to it," she observes.

Noy hopes to perfect the technique so that researchers can develop an approach to introduce CRABP-II in specific tissues and thereby influence target-gene expression.

The research was supported, in part, by the National Institutes of Health, the Swiss National Science Foundation and the Novartis Foundation.


Story Source:

The above story is based on materials provided by Cornell University. Note: Materials may be edited for content and length.


Cite This Page:

Cornell University. "Reducing Side Effects Of Retinoic Acid Cancer Treatment." ScienceDaily. ScienceDaily, 15 August 2002. <www.sciencedaily.com/releases/2002/08/020814070155.htm>.
Cornell University. (2002, August 15). Reducing Side Effects Of Retinoic Acid Cancer Treatment. ScienceDaily. Retrieved April 1, 2015 from www.sciencedaily.com/releases/2002/08/020814070155.htm
Cornell University. "Reducing Side Effects Of Retinoic Acid Cancer Treatment." ScienceDaily. www.sciencedaily.com/releases/2002/08/020814070155.htm (accessed April 1, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Wednesday, April 1, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

7-Year-Old Girl Gets 3-D Printed 'robohand'

7-Year-Old Girl Gets 3-D Printed 'robohand'

AP (Mar. 31, 2015) — Although she never had much interest in prosthetic limbs before, Faith Lennox couldn&apos;t wait to slip on her new robohand. The 7-year-old, who lost part of her left arm when she was a baby, grabbed it as soon as it came off a 3-D printer. (March 31) Video provided by AP
Powered by NewsLook.com
Solitair Device Aims to Takes Guesswork out of Sun Safety

Solitair Device Aims to Takes Guesswork out of Sun Safety

Reuters - Innovations Video Online (Mar. 31, 2015) — The Solitair device aims to take the confusion out of how much sunlight we should expose our skin to. Small enough to be worn as a tie or hair clip, it monitors the user&apos;s sun exposure by taking into account their skin pigment, location and schedule. Matthew Stock reports. Video provided by Reuters
Powered by NewsLook.com
Soda, Salt and Sugar: The Next Generation of Taxes

Soda, Salt and Sugar: The Next Generation of Taxes

Washington Post (Mar. 30, 2015) — Denisa Livingston, a health advocate for the Dinι Community Advocacy Alliance, and the Post&apos;s Abby Phillip discuss efforts around the country to make unhealthy food choices hurt your wallet as much as your waistline. Video provided by Washington Post
Powered by NewsLook.com
UnitedHealth Buys Catamaran

UnitedHealth Buys Catamaran

Reuters - Business Video Online (Mar. 30, 2015) — The $12.8 billion merger will combine the U.S.&apos; third and fourth largest pharmacy benefit managers. Analysts say smaller PBMs could also merge. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins